Spyre Therapeutics IBD drug shows promise in early trial

Summary: Spyre Therapeutics has good news for people with inflammatory bowel disease (IBD). Their new experimental drug, called SPY001, did very well in an early test. The medicine works by targeting a specific pathway to calm down swelling in the gut. In the study, 40% of patients saw their symptoms completely go away after just 12 weeks of treatment. This early success means Spyre is ready to compete with bigger companies making similar medicines for stomach issues.

Source: rssapp-statnews-com URL: statnews.com/2026/04/13/spyre-ibd-drug-success-early-trial/ (opens in new tab)